Asan Medical Center: Breast Neoplasms trials
The registry lists 15 Breast Neoplasms studies with Asan Medical Center as lead sponsor. 3 are open to participants now and 0 have results posted.
Phase 2 6Phase 3 3No phase 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Predicting Endocrine Resistance Using Molecular Imaging and Liquid Biopsy in Metastatic Breast CancerNot yet recruitingNCT07867925
- [18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast CancerRecruitingNCT07314073Phase 2
- Effect of Preoperative Exercise on the Prevention of Secondary Lymphedema in Breast Cancer PatientsRecruitingNCT06421285Not applicable
- Music and Surgery Associated With Relationship and SatisfactionStatus unknownNCT04555057Not applicable
- Distress Reduction by Activity Tracking and Activity Enhancement by Mobile Support Group in OncologyCompletedNCT03783481Not applicable
- Development of Exercise Promotion Program Using a Mobile CommunityCompletedNCT03190720Not applicable
- Development of Distress Management Algorithms Using Mobile Device Based Health Logs in Breast Cancer SurvivorsCompletedNCT03072966Not applicable
- Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)TerminatedNCT02685111Phase 2
- Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast CancerCompletedNCT02344550Phase 2
- Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast CancerCompletedNCT02263495Phase 2
- Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negative Breast Cancer for Neoadjuvant ChemotherapyCompletedNCT02001519Phase 2
- Neoadjuvant Chemotherapy of 6 Cycles vs 8 Cycles in Node Positve Breast CancerCompletedNCT02001506Phase 3
- Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast CancerCompletedNCT01986569Phase 3
- Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast CancerStatus unknownNCT01622361Phase 3
- Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast CancerCompletedNCT01275859Phase 2